The combination of checkpoint immunotherapy and targeted therapy in cancer

被引:56
作者
Karachaliou, Niki [1 ]
Gonzalez-Cao, Maria [2 ]
Sosa, Aaron [1 ]
Berenguer, Jordi [3 ]
Paulina Bracht, Jillian Wilhelmina [3 ]
Ito, Masaoki [4 ]
Rosell, Rafael [5 ,6 ]
机构
[1] Univ Hosp Sagrat Cor, IOR, C Viladomat 288, Barcelona 08029, Spain
[2] Quiron Dexeus Univ Inst, IOR, Barcelona, Spain
[3] Quiron Dexeus Univ Inst, Pangaea Oncol, Barcelona, Spain
[4] Hiroshima Univ, Res Inst Radiat Biol & Med, Dept Surg Oncol, Hiroshima, Japan
[5] Germans Trias & Pujol Res Inst, Badalona, Spain
[6] Germans Trias & Pujol Univ Hosp, Catalan Inst Oncol, Badalona, Spain
关键词
Immune checkpoint blockade (ICB); targeted therapies; melanoma; lung cancer; BRAF; epidermal growth factor receptor (EGFR); CELL LUNG-CANCER; T-CELL; PD-L1; EXPRESSION; BRAF INHIBITION; ACQUIRED-RESISTANCE; ANTIGEN-EXPRESSION; ANTITUMOR-ACTIVITY; IMPROVED SURVIVAL; IMMUNE ESCAPE; OPEN-LABEL;
D O I
10.21037/atm.2017.06.47
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The therapeutic possibilities for patients with metastatic melanoma have changed due to the development of targeted therapies that inhibit oncogenic signaling pathways as well as immune modulating therapies that unleash the patient antitumor immunity. These therapeutic changes have impressively increased the median overall survival of the patients. Considering the dramatic but transient responses that occur with targeted therapies for a subgroup of patients and the durable responses that can be achieved with immunotherapy in a subset of patients, a lot of effort is ongoing for the clinical development of combinations of these two therapeutic approaches. Herein we discuss the existing preclinical and clinical data for the combination of targeted therapies and immunotherapy focusing mainly on melanoma and non-small cell lung cancer (NSCLC).
引用
收藏
页码:1 / 10
页数:10
相关论文
共 59 条
[1]   Osimertinib combined with durvalumab in EGFR-mutant non-small cell lung cancer: Results from the TATTON phase Ib trial [J].
Ahn, M. -J. ;
Yang, J. ;
Yu, H. ;
Saka, H. ;
Ramalingam, S. ;
Goto, K. ;
Kim, S. -W. ;
Yang, L. ;
Walding, A. ;
Oxnard, G. R. .
JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (04) :S115-S115
[2]   Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors [J].
Akbay, Esra A. ;
Koyama, Shohei ;
Carretero, Julian ;
Altabef, Abigail ;
Tchaicha, Jeremy H. ;
Christensen, Camilla L. ;
Mikse, Oliver R. ;
Cherniack, Andrew D. ;
Beauchamp, Ellen M. ;
Pugh, Trevor J. ;
Wilkerson, Matthew D. ;
Fecci, Peter E. ;
Butaney, Mohit ;
Reibel, Jacob B. ;
Soucheray, Margaret ;
Cohoon, Travis J. ;
Janne, Pasi A. ;
Meyerson, Matthew ;
Hayes, D. Neil ;
Shapiro, Geoffrey I. ;
Shimamura, Takeshi ;
Sholl, Lynette M. ;
Rodig, Scott J. ;
Freeman, Gordon J. ;
Hammerman, Peter S. ;
Dranoff, Glenn ;
Wong, Kwok-Kin .
CANCER DISCOVERY, 2013, 3 (12) :1355-1363
[3]  
[Anonymous], 2015, J CLIN ONCOL S
[4]  
[Anonymous], 2014, J CLIN ONCOL
[5]  
Besse B, 2016, J THORAC ONCOL, V12, pS397
[6]   Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma [J].
Bollag, Gideon ;
Hirth, Peter ;
Tsai, James ;
Zhang, Jiazhong ;
Ibrahim, Prabha N. ;
Cho, Hanna ;
Spevak, Wayne ;
Zhang, Chao ;
Zhang, Ying ;
Habets, Gaston ;
Burton, ElizabethA. ;
Wong, Bernice ;
Tsang, Garson ;
West, Brian L. ;
Powell, Ben ;
Shellooe, Rafe ;
Marimuthu, Adhirai ;
Nguyen, Hoa ;
Zhang, Kam Y. J. ;
Artis, Dean R. ;
Schlessinger, Joseph ;
Su, Fei ;
Higgins, Brian ;
Iyer, Raman ;
D'Andrea, Kurt ;
Koehler, Astrid ;
Stumm, Michael ;
Lin, Paul S. ;
Lee, Richard J. ;
Grippo, Joseph ;
Puzanov, Igor ;
Kim, Kevin B. ;
Ribas, Antoni ;
McArthur, Grant A. ;
Sosman, Jeffrey A. ;
Chapman, Paul B. ;
Flaherty, Keith T. ;
Xu, Xiaowei ;
Nathanson, Katherine L. ;
Nolop, Keith .
NATURE, 2010, 467 (7315) :596-599
[7]   Selective BRAFV600E Inhibition Enhances T-Cell Recognition of Melanoma without Affecting Lymphocyte Function [J].
Boni, Andrea ;
Cogdill, Alexandria P. ;
Dang, Ping ;
Udayakumar, Durga ;
Njauw, Ching-Ni Jenny ;
Sloss, Callum M. ;
Ferrone, Cristina R. ;
Flaherty, Keith T. ;
Lawrence, Donald P. ;
Fisher, David E. ;
Tsao, Hensin ;
Wargo, Jennifer A. .
CANCER RESEARCH, 2010, 70 (13) :5213-5219
[8]   BRAFV600E Co-opts a Conserved MHC Class I Internalization Pathway to Diminish Antigen Presentation and CD8+ T-cell Recognition of Melanoma [J].
Bradley, Sherille D. ;
Chen, Zeming ;
Melendez, Brenda ;
Talukder, Amjad ;
Khalili, Jahan S. ;
Rodriguez-Cruz, Tania ;
Liu, Shujuan ;
Whittington, Mayra ;
Deng, Wanleng ;
Li, Fenge ;
Bernatchez, Chantale ;
Radvanyi, Laszlo G. ;
Davies, Michael A. ;
Hwu, Patrick ;
Lizee, Gregory .
CANCER IMMUNOLOGY RESEARCH, 2015, 3 (06) :602-609
[9]   Lung Cancer Subtypes Generate Unique Immune Responses [J].
Busch, Stephanie E. ;
Hanke, Mark L. ;
Kargl, Julia ;
Metz, Heather E. ;
MacPherson, David ;
Houghton, A. McGarry .
JOURNAL OF IMMUNOLOGY, 2016, 197 (11) :4493-4503
[10]   Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC [J].
Chaib, Imane ;
Karachaliou, Niki ;
Pilotto, Sara ;
Codony Servat, Jordi ;
Cai, Xueting ;
Li, Xuefei ;
Drozdowskyj, Ana ;
Codony Servat, Carles ;
Yang, Jie ;
Hu, Chunping ;
Felipe Cardona, Andres ;
Vivanco, Guillermo Lopez ;
Vergnenegre, Alain ;
Miguel Sanchez, Jose ;
Provencio, Mariano ;
de Marinis, Filippo ;
Passaro, Antonio ;
Carcereny, Enric ;
Reguart, Noemi ;
Garcia Campelo, Charo ;
Teixido, Cristina ;
Sperduti, Isabella ;
Rodriguez, Sonia ;
Lazzari, Chiara ;
Verlicchi, Alberto ;
de Aguirre, Itziar ;
Queralt, Cristina ;
Wei, Jia ;
Estrada, Roger ;
Puig de la Bellacasa, Raimon ;
Luis Ramirez, Jose ;
Jacobsen, Kirstine ;
Ditzel, Henrik J. ;
Santarpia, Mariacarmela ;
Viteri, Santiago ;
Angel Molina, Miguel ;
Zhou, Caicun ;
Cao, Peng ;
Ma, Patrick C. ;
Bivona, Trever G. ;
Rosell, Rafael .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2017, 109 (09)